NeuroSense Shareholders Approve Reverse Split Up to 1-for-40
NRSN sits 76% above its 52-week low of $0.25 on light trading volume (0.2× avg).
Summary
NeuroSense shareholders approved a reverse split authorization with a ratio range of 1-for-4 to 1-for-40, with the Board to decide the exact ratio and timing within 12 months.
Key Events · Corporate Governance and Compliance · NRSN
-
Reverse Split Authorization Approved
Shareholders approved authorizing the Board to effect one or more reverse splits at an aggregate ratio of 1-for-4 to 1-for-40, with the exact ratio and effective date to be determined by the Board within 12 months.
-
Board Discretion on Ratio and Timing
The Board can choose the exact ratio and effective date, if any, within the approved range and 12-month window, providing flexibility to respond to Nasdaq listing requirements.
-
No Articles Amendment Required
Shareholders also approved that no amendment to the Company's Articles of Association is required in connection with any reverse split.
-
Nasdaq Compliance Context
The reverse split authorization follows prior disclosures of Nasdaq delisting risk and a dwindling ATM facility, with the stock trading near $0.44.
Analysis · NRSN · Life Sciences
At the August 26 special meeting, shareholders approved a reverse split authorization, giving the Board discretion to implement a ratio between 1-for-4 and 1-for-40 within 12 months. This is the expected follow-through to the July 31 meeting notice, but the approved range is material: a 1-for-40 split would reduce the share count dramatically and is aimed at regaining Nasdaq compliance. The Board now has the tool to act quickly if needed, which matters for a company trading near $0.44 with delisting risk already disclosed in prior filings.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1753 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRSN was trading at $0.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.6M. The 52-week trading range was $0.25 to $1.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.